losartan has been researched along with Cholangiocarcinoma in 1 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Cholangiocarcinoma: A malignant tumor arising from the epithelium of the BILE DUCTS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saikawa, S | 1 |
| Kaji, K | 1 |
| Nishimura, N | 1 |
| Seki, K | 1 |
| Sato, S | 1 |
| Nakanishi, K | 1 |
| Kitagawa, K | 1 |
| Kawaratani, H | 1 |
| Kitade, M | 1 |
| Moriya, K | 1 |
| Namisaki, T | 1 |
| Mitoro, A | 1 |
| Yoshiji, H | 1 |
1 other study available for losartan and Cholangiocarcinoma
| Article | Year |
|---|---|
Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein.
Topics: Adaptor Proteins, Signal Transducing; Angiotensin Receptor Antagonists; Animals; Bile Duct Neoplasms | 2018 |